Wassil Jim 4

4 · Vaxcyte, Inc. · Filed Mar 2, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

Vaxcyte (PCVX) COO Wassil Jim Receives RSUs, Surrenders Shares

What Happened

Wassil Jim, Chief Operating Officer of Vaxcyte (PCVX), received multiple equity awards and had shares withheld to cover tax obligations. The filing shows three grants: 32,045 RSUs (time‑based, $0 per share), 5,102 RSUs issued in lieu of a cash bonus (acquired at $61.74, total value $314,997), and a 53,566‑share derivative award (option/other, $0 stated).
To satisfy tax withholding on vested RSUs, Jim surrendered 3,807 shares across three dates (1,900 @ $61.74 = $117,306; 898 @ $61.98 = $55,658; 1,009 @ $61.98 = $62,538), totaling $235,502 in withheld value. Net from the cash‑in‑lieu award: 5,102 granted → 3,807 withheld → about 1,295 shares remaining (≈$80k at ~ $61.7/share).
Overall headline: ~90,713 shares were reported in awards/derivatives (32,045 + 5,102 + 53,566), but the majority (32,045 RSUs and 53,566 derivative shares) appear unvested per the filing.

Key Details

Transaction dates and prices: 2/26/2026 (32,045 RSUs @ $0.00; 53,566 derivative @ $0.00), 2/27/2026 (5,102 RSUs @ $61.74, value $314,997; 1,900 shares surrendered @ $61.74), 2/28/2026 (898 shares surrendered @ $61.98), 3/02/2026 (1,009 shares surrendered @ $61.98).
Total value reported for vested award: $314,997; total value surrendered for taxes: $235,502.
Footnotes: F1 = standard time‑based RSU vesting schedule (1/4 on 9/7/2026 then 1/8 every six months); F2 = RSUs issued in lieu of a cash bonus and fully vested at grant; F3 = shares surrendered to cover tax withholding; F4 = derivative (option) vests 1/48 on 3/26/2026 then monthly thereafter.
Shares owned after the transactions are not specified in the filing.
Filing date: Form 4 filed 2026‑03‑02 for report period beginning 2026‑02‑26 — filing appears timely under the 2 business‑day rule.

Context

The 5,102 RSUs were issued in lieu of a cash bonus and were fully vested at grant; the surrendered shares represent tax withholding (routine, not an open‑market sale).
The larger 32,045 RSU award and the 53,566‑share derivative (option) award are subject to future vesting schedules and do not reflect immediate sell/buy market activity.
These transactions are largely compensation and tax withholding events — common for executives — rather than open‑market purchases or discretionary sales.

Form 4

Period: 2026-02-26

CHIEF OPERATING OFFICER

Transactions

Award
Common Stock
[F1]
2026-02-26+32,045→ 173,893 total
Award
Common Stock
[F2]
2026-02-27$61.74/sh+5,102$314,997→ 178,995 total
Tax Payment
Common Stock
[F3]
2026-02-27$61.74/sh−1,900$117,306→ 177,095 total
Tax Payment
Common Stock
[F3]
2026-02-28$61.98/sh−898$55,658→ 176,197 total
Tax Payment
Common Stock
[F3]
2026-03-02$61.98/sh−1,009$62,538→ 175,188 total
Award
Stock Option (right to buy)
[F4]
2026-02-26+53,566→ 53,566 total
Exercise: $60.00Exp: 2036-02-26→ Common Stock (53,566 underlying)

Footnotes (4)

[F1]Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
[F2]Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant.
[F3]Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
[F4]1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Signature

Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact|2026-03-02

1 file